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Abstract 
Purpose of review: Patients with traumatic brain injury (TBI) are typically multiple 
trauma patients, presenting with various pathological entities that jeopardize their 
survival. Anemia is one of the most common abnormalities in trauma patients, and is 
considered a worse prognosis determinant. However, strong recommendations, and high-
quality prospective studies to support the best transfusion practices in brain trauma 
patients are scarce, if not inexistent, leading to major doubts in optimal treatments. This 
review’s intention is to summarized actual evidence regarding this issue, mainly the 
hemoglobin thresholds and other important triggers used in treating anemic TBI patients. 
Recent findings: In general, in intensive and in neurocritical care, a restrictive 
transfusion method has been proven safe and, at least, not inferior to previously advocated 
liberal thresholds. Nevertheless, other physiological variables have been recently studied 
in treating anemia in this patients’ population, leading to more liberal approaches in red 
blood cell transfusions, due to recent implemented “triggers”. Allowing a normal oxygen 
delivery and achieving an optimal brain oxygenation is dependent of multiple factors, 
independent of hemoglobin concentrations. 
Summary: Nowadays, there is no sufficiently high-quality information to provide strong 
general recommendations in managing anemia in traumatic brain injury. Transfusions are 
one of the main options, but they have both benefits and risks that must be taken in 
account in every single case.  
Keywords: Red blood cell transfusions, anemia, traumatic brain injury, brain 
oxygenation, intensive care, hemoglobin 
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Introduction 
Anemia in adult patients is defined by a blood hemoglobin concentration below 12 g/dL 
(women) or below 13 g/dL (men), and can be classified in severity as mild (11-11,9 g/dL 
for women, 11-12,9 g/dL for men), moderate (8-10,9 g/dL, for both genders), or severe 
(below 8 g/dL, for both genders) 1.  
Traumatic Brain Injury (TBI) is one of the major causes for admission in the Neurocritical 
Care Unit (NCCU), being responsible for approximately 30% of all injury-related deaths 
in the United States 2. 
Anemia develops in at up to half of all TBI patients, and is a risk factor for secondary 
brain damage and, therefore, worse prognosis 3. 
As transfusion of red blood cell units is considered a vital tool for early resuscitation of 
anemic patients in critical situations 4, studies have been conducted regarding which 
should be the most appropriate threshold, mainly based in hemoglobin concentrations, for 
transfusion in ICU and, specifically, in TBI patients, with controversial results. 
Due to the lack of strong evidence-based recommendations for transfusion practices in 
TBI patients, mainly to the very few randomized controlled trials conducted on this 
problem, and the inconsistency in results from previous low-quality studies, practicians 
are not able to treat this patients’ population in a secure and accurate manner. 
 
Methods 
Using the terms “anemia”, “traumatic brain injury” and “blood transfusion” in the 
database PUBMED, articles were selected and included in this review, based on their 
relevance and adequacy towards the subject. 
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Discussion 
Epidemiology of TBI 
In 2010, TBI caused almost 2.5 million emergency department (ED) visits, 
hospitalizations, or deaths, representing an increase of ED visits due to TBI by 70%, while 
hospitalization and death rates only increased by 11% and 7%, respectively. The direct 
and indirect costs associated with this clinical entity are more than substantial 5. 
In 2017, the Center for Disease Control published a report on TBI 6, where they stated 
that most injuries resulting in TBI lead to emergency department’ visits (ED), while 
hospitalizations and deaths occurred in a minority of cases. Of all the emergency 
department’ visits, hospitalizations and deaths registered in the United States in 2013, 
only 1,9% were due to TBI, the equivalent of one in every 50 ED visits, and 2,2% of all 
deaths.  
When analyzed by age groups, TBI’s diagnosis was more common in extreme ages, such 
as elderly people older than 75 years, infants (0-4 years) and young adults (15-24 years). 
The same happened in ED visits, where young adults were the main contributing age 
group (17,9% of all TBI-related ED visits).  However, hospitalizations and deaths were 
more frequent only the oldest age groups (≥65 years), especially in those older than 75 
years (31,4%, and 26,5% of hospitalizations and deaths related to TBI, respectively). 
Falls (47,2%), object collisions (15,4%) and motor accidents (13,7%) were the most 
common mechanisms of injury. Falls happened more frequently in very young (0-4 years) 
and elderly individuals (≥65 years), whereas object collisions and motor accidents 
typically occurred in children and adults (0-24 years, and 15-44 years, respectively). TBI 
was also more frequent in men than women (1,14 times more common), except for the 
cases of falls as the mechanism of injury 6. 
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Affecting 2% of the USA’s population every year, TBI is an important pathological 
entity, with significant mortality and morbidity. Each case can vary from mild 
concussions which only require surveillance, to large hemorrhages that need urgent 
surgical interventions (such as evacuation of hematomas) 7. Despite the technological 
advances in the field of intensive care and neuromonitoring, 20% of patients die, and 35% 
of the survivors suffer with debilitating neurological deficits 8. 
 
Oxygen and Blood Supply to the Brain 
As in every other organ in the human body, the oxygen delivery (DO2) to the brain tissues 
depends on the cardiac output (CO), which determines the cerebral blood flow (CBF), 
and the arterial content of oxygen (CaO2).  
At the same time, CO depends on the stroke volume (SV) and heart rate (HR), whereas 
CaO2 depends mostly on the hemoglobin concentration (Hb) and its rate of saturation 
with oxygen (SaO2%), with a minor contribution from oxygen dissolved in the blood 
(PaO2). The equations supporting the physiology of oxygen delivery are the following:  
 𝐷𝑂2	(𝑚𝐿	𝑂2/𝑚𝑖𝑛) 	= 	𝐶𝐵𝐹	(𝐿/𝑚𝑖𝑛)	𝑥	𝐶𝑎𝑂2	(𝑚𝐿	𝑂2/𝐿) 𝐶𝐵𝐹	(𝐿/𝑚𝑖𝑛) 	= 	𝑆𝑉	(𝐿/𝑐𝑜𝑛𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛)	𝑥	𝐻𝑅	(𝑐𝑜𝑛𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑠/𝑚𝑖𝑛𝑢𝑡𝑒) 𝐶𝑎𝑂2	 = 	 [1,39	𝑥	𝐻𝑏	(𝑔/𝐿)	𝑥	𝑆𝑎𝑂2	(%)] 	+	 [0.003	𝑥	𝑃𝑎𝑂2	(𝑚𝑚	𝐻𝑔)] 
 
The flow of blood through the brain’s microcirculation is also dependent of other 
variables, including the radius of the vessel (r), the differential of pressures between two 
areas (∆P), the blood’s viscosity (ƞ), and the vessel’s length (L). ∆P can be represented 
in the cerebral system by the cerebral perfusion pressure (CPP). The Hagen-Poiseuille 
equation demonstrates the relation between all the variables presented: 
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𝐹𝑙𝑜𝑤 = 	𝜋	𝑥	𝑟4	𝑥	𝐶𝑃𝑃8	𝑥	𝜂	𝑥	𝐿  
 
By analyzing this equation, it can be inferred that vasodilation (increase of the radius of 
the vessel) and increase of CPP lead to higher blood flow to the brain, while a increase in 
viscosity (𝛈), as in dehydration states or after a red blood cell transfusion (RBCT), leads 
to the opposite effect. Also, it is important to highlight that, due to the fourth power 
inputted on the radius of the vessel, small changes in vessel’s diameter can lead to grand 
variations in the CBF. 
In order to determine if CBF is enough to allow sufficient or even normal brain 
oxygenation, intensivists calculate the CPP, using the formula: 
 𝐶𝑃𝑃	(𝑚𝑚𝐻𝑔) 	= 	𝑀𝐴𝑃	– 	𝐼𝐶𝑃 
 
MAP is the Mean Arterial Pressure, easily measurable with manual or automatic 
sphygmomanometer, and ICP is the Intracranial Pressure, measured through intracranial 
probes, with normal values being 7-15 mmHg, and values above 20-25 mmHg needing 
medical intervention. A raise on MAP leads to higher CPP levels, which can aggravate 
preexistent cerebral edema, while elevation of ICP (such as in TBI) reduces CPP, with 
subsequent risk of ischemia.  
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The Effects of Anemia in the Brain’s Physiology 
The human brain is one of the organs with the highest oxygen extraction rate (OER) and 
consumption of oxygen (VO2) for its basic metabolic necessities. The oxygen being 
continuously delivered to the brain by the cardiovascular system is mostly absorbed and 
utilized in the production of energy.  
Anemia, due to the decrease in hemoglobin concentrations, leads to a major decrease in 
the CaO2 and the oxygen delivered to the brain. This results in inadequate DO2, incapable 
of meeting the cerebral metabolic rate for oxygen consumption (CMRO2), leading to 
tissue ischemia. CMRO2 can be determined by the following equation, where AVDO2 is 
the arterial-jugular oxygen content difference: 
 
𝐶𝑀𝑅𝑂2	(𝑚𝐿/𝑚𝑖𝑛/100𝑔) 	= 	𝐴𝑉𝐷𝑂2	𝑥	𝐶𝐵𝐹100  
 
In acute anemia states, as a countermeasure, CBF is preferentially raised, compared to 
the flow to other lesser vital organs 9, through various compensatory mechanisms, as 
shown in experimental studies in healthy individuals. These include: 
  
(1) Sympathetic stimulation: carotid and aortic chemoreceptors detect a decrease in the 
arterial content of oxygen and respond by activating the sympathetic nervous system, 
resulting in higher blood pressure (systemic vasoconstriction) and cardiac work 
(elevation of the heart rate and of the left ventricular stroke volume) 10; also, the 
upregulation of 	ß2 receptors in the blood vessels leads to cerebral vasodilation 11; this 
guarantees a rise in CBF to counterbalance the lower CaO2 present in anemia, in order to 
maintain a proper DO2.  
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(2) Anemia itself, due to a lower number and concentration of red blood cells (lower 
hematocrit), leads to a decrease in blood viscosity, which facilitates blood flow through 
the cerebral microcirculation 12; it also increases venous return and reduces systemic 
vascular resistance, with a resulting additive effect to the improvement of oxygen delivery 
to the brain 13. 
  
(3) The encephalic cells, namely endothelial cells, perivascular astrocytes and neurons, 
produce nitric oxide (NO) in response to lower oxygen availability 14, which in turn leads 
to relaxation of the vascular smooth muscle cells, resulting in dilation of the cerebral 
vessels, and a substantially higher CBF 15. 
  
(4) In response to a partial or total deficit of oxygen, the brain responds by rising its 
oxygen extraction rate 16, in order to maintain its metabolic energy production and avoid 
the use of anaerobiosis, which results in the buildup of lactate, reactive oxygen species 
and other prejudicial metabolites that can worsen the overall state of the brain’s health 
and jeopardize the patient’s survival 11. 
  
(5) In severe anemia, cerebral hypoxia induces the cellular production of HIF (hypoxia-
inducible factor), a transcription factor that allows cells to adapt to low-oxygen states, 
protecting them from ischemia 17; it also stimulates the renal production of EPO 
(erythropoietin), a hematopoietic stimulator of the bone marrow, as well as a inhibitor of 
neuroral apoptosis with neuroprotective effects 18, and the production of VEGF (vascular 
endothelial growth factor), a angiogenesis stimulator that allows long-term adaptations to 
hypoxia 19. 
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(6) Hemoglobin itself functions as a oxygen sensor, stimulating the release of local-acting 
vasodilators, in response to tissue hypoxia, such as NO (nitric oxide) and ATP 
(adenosine-5’-triphosphate), increasing regional blood flow, in order to balance the 
delivery of oxygen with its consumption 20. 
 
Part of this mechanisms are intrinsic to the brain tissue, being commonly reffered to as 
“cerebral autoregulation”, that allow, collectively, the brain’s self-adaptation to a wide 
variations of systemic variables, for instance, the capacity to withheld wide variations of 
systemic arterial pressure while maintaining a relatively constant CBF 21,22.  
Although these mechanisms are effective and allow normalization of cerebral DO2 in 
anemic patients, there is a critical threshold value for hemoglobin concentration at which 
the brain’s compensatory mechanisms start to fail, estimated at 5-6 g/dL 12 . After this 
point is reached, maximum vasodilation and CBF values are reached, cerebral DO2 starts 
to diminish, tissue ischemia and hypoxia establish, and changes of the mental status and 
cognitive deficits start to develop 23.  
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Red Blood Cell Transfusion (RBCT) in Critical Care 
In critical care, blood transfusion is still a live-saving procedure and its early and 
aggressive use is essential for resuscitating patients with massive hemorrhages, especially 
in the context of trauma 4. Transfusions are used, not only as a initial measure of 
treatment, but also in the management of critically ill patients who suffer from potentially 
complicating anemia, reason why at least 50% of these patients receive more than one 
unit of RBC’s during their stay in the ICU 24. Although the physiological rationale of 
raising the arterial content of oxygen (CaO2) and, therefore, the DO2 for the body’s 
tissues in risk of ischemia 21, was the argument for a mainly “liberal” use of RBCT , more 
and more evidence, published and discussed over decades, lead to the conclusion that a 
more restrictive use of RBCT would likely be equally or even superiorly beneficial for 
patients, due to the reduction of complications and adverse effects associated with 
transfusion of blood products (25,26). 
In fact, most retrospective studies done on this issue show an association between 
“liberal” transfusion strategies and negative outcomes, such as higher mortality rates, 
multi-organ failure 27, nosocomial infections (due to immunosuppression) 28, respiratory 
and cardiac complications (namely, ARDS) 29, and longer hospital stay 30.  
Complications of blood transfusions can be classified as “common” to all blood products, 
or “specific” of individual blood components. “Common” complications are the majority 
(85,5% of all report incidents) of transfusion-related complications (85,5% of all report 
incidents), and are mostly related to errors in administration, such as: ABO-incompatible 
RBCT; anti-D immunoglobin errors; transfusion of the wrong blood component (IBCT); 
handling and storage errors; delays in transfusion; over or avoidable administration of 
blood components; and nonspecific reactions to transfusions (FAHR – Febrile, allergic 
and hypotensive reactions) 31.  
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More specific complications are more serious and life-threatening, though possibly 
preventable. This include: Transfusion-Associated Circulatory Overload (TACO), 
Haemolytic transfusion reactions (HTR), Transfusion-associated dyspnea (TAD), 
Transfusion-related acute lung injury (TRALI), Post-transfusion Purpura (PTP), and 
Transfusion-associated graft-vs-host disease (TAGvHD). In the intensive care unit, the 
most common, lethal, and difficult to manage situations are TACO, TAD and TRALI, 
which contribute to 44,1%, 5,9% and 3,7%, respectively, of the 53,7% of transfusion-
related deaths due to respiratory complications.  
 
Effects of Anemia in TBI 
Anemia is common in intensive care units, affecting up to 70% of critically ill patients 32, 
and 50% of severe TBI patients 33. It has been demonstrated a tendency of daily decrease 
of hemoglobin levels of 0,5 g/dL, while in ICU stay 34.  
In neurocritical care patients, the etiology of anemia is multifactorial 35, similarly to other 
ICU patients populations, with causes including: blood loss, due to hemorrhages or 
medical procedures (e.g. frequent phlebotomies); myelosuppression, with a consequent 
decrease in production of hematopoietic cells, and elevated consumption of red blood 
cells, secondary to systemic inflammation 36; abnormalities in the EPO and iron 
metabolisms; hemodilution secondary to intravenous fluid resuscitation and hemorrhages 
37. 
After initial damage to the brain tissue, changes in the brain’s metabolism and 
autoregulation processes can lead to secondary brain injury, mainly tissue acidosis and 
ischemia 21, which can be even greater than the primary injury, caused by a multitude of 
neurocritical entities, including TBI. The existence of so-called “ischemic penumbra” 
areas, areas of brain tissue between normal and infarcted areas, with mild to moderate 
ischemia, are of “high-risk”, as they are particularly vulnerable to even subtle changes in 
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the delivery of oxygen and, therefore, must be closely monitored to avoid propagation of 
irreversible damage 38. 
Anemia, hypoxemia and hypotension are systemic, reversible causes of secondary injury, 
and many other factors contribute to the worsening of this damage, such as: intracranial 
hypertension, vasospasm (typically after SAH), loss of autoregulation, and the 
uncoupling of blood flow and metabolic pathways 39. 
Anemia is, therefore, less well tolerated by patients with acute neurological stress, such 
as TBI, as alterations in the oxygen delivery and in oxygen-dependent metabolic 
pathways, increase the risk for secondary ischemia. 
 
In response to the lack of oxygen availability to produce metabolic energy in the 
mitochondria, the neuronal cells utilize the pyruvate produced from glucose oxidation in 
the cytosol, and transformed it into lactate, through the oxygen-independent process of 
lactic fermentation. This process allows the cells to obtain energy from glucose in anoxic 
environments, with the downside of endangering their own survival, due to lactic acidosis 
that can abolish vital cellular mechanisms 40.  
Therefore, evaluation of systemic lactate concentrations (through blood samples) and the 
regional lactate:pyruvate ratio/LPR (through cerebral microdialysis probes), allows 
practicians to determine the state of the brain’s metabolism, and provides information 
about the risk of neurological dysfunction, in low oxygen states such as anemia 41.  
These metabolic measures serve as indirect predictors of the CMRO2.  
As so, one prospective study done in 28 severe TBI patients, determined that low 
hemoglobin levels were related to higher lactate differences, and, therefore, a important 
predictor of brain ischemia 42. These differences can be caused by a decrease in CMRO2, 
where less utilization of oxygen leads to anaerobiosis, as it was shown in a similar 
prospective study done in 64 acute brain injury patients, undergoing serial 133xenon 
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studies for monitoring of regional cerebral blood flow and global cerebral oxygen 
metabolism 43. 
 
Another way of evaluating the effects of anemia in the human brain is by measuring of 
the brain tissue’s partial oxygen pressure, or PbtO2, through invasive probes placed in 
strategic regions in the cerebral cortex 44. This innovative tool is being increasingly used 
in intensive care, as a means of guiding treatment in patients with acute brain injury 45. It 
allows practicians to have a proper idea of the actual balance between oxygen delivery 
and consumption 46, which is altered in these patients due to various pathological entities, 
such as perivascular edema, cytotoxic cell swelling, arteriovenous shunting and 
microvascular collapse 47.  
PbtO2 is considered normal for values between 25 and 30 mmHg 45, and its reduction 
presents a stronger correlation with deficits in oxygen diffusion through the blood-brain 
barrier and throughout cerebral tissue 48, than it presents with decreased oxygen delivery. 
In neurocritical care, the minimum goal value for PbtO2 is 20 mmHg 49, has prognosis 
worsens in lower levels, with 10 mmHg being considered the critical threshold, as it is 
associated with irreversible neuronal damage and poor outcomes 45. 
In TBI, anemia is not always associated to low PbtO2 50. Nevertheless, one experimental 
study conducted in 80 severe TBI patients, found that patients with anemia (<9g/dL) and 
concomitant low PbtO2 (<20 mmHg) had significant worse neurological outcomes, 
independently of injury severity, while isolated anemia patients did not 51.  
 
Although a large body of evidence exists, regarding the effects of anemia in healthy 
patients, these data cannot be interpreted in the same way, when referring to TBI patients. 
The studies conducted in healthy individuals used lower controlled levels of hemoglobin 
52, and this patients had an higher “cerebrovascular reserve”, defined as the ability of the 
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brain’s vascular system to respond to different stimuli via vasodilation, when compared 
to brain-injured patients 53, who are also at a higher risk of developing conditions, such 
as hemodynamic instability, that can jeopardize their compensatory mechanisms 54. 
In TBI, anemia has been inconsistently associated with worse outcomes. This variance in 
results is believed to be related to different endpoints, outcome measures and cut-off 
points used, as well as the uncertainty surrounding the actual clinical effect produced by 
significant changes in outcomes.  
Also, sometimes, significant correlations between anemia and mortality or poor 
neurological outcomes, become non-significant, after taking in account other disease-
related variables, as in a retrospective study by Carlson et al. 55, where, while studying 
outcomes in 169 severe TBI patients, correction for disease severity and other predictors 
of adverse outcomes transformed a significant association between anemia and mortality 
into a non-significant one.  
Nevertheless, most studies show that anemia, either present at baseline and/or during stay 
in the ICU, is a risk factor for mortality and other adverse outcomes. 2 large studies 
(CRASH trial 56 and IMPACT study 57) found that lower admission Hb levels were 
associated with worse outcome, especially for levels lower than 9 g/dL, which were also 
associated with metabolic distress in previous brain physiological studies 58. On the other 
hand, one review showed that a baseline Hb < 10g/dL was a not a risk factor for 
mortality59. 
Also, it is considered that repeated measures of hemoglobin levels are more valuable than 
baseline levels, for the prediction of worse outcomes. In fact, development of anemia in 
the ICU (Hb < 9g/dL) 60, a mean Hb < 9 g/dL in the first seven days of admission 33, and 
a higher number of days with hematocrit < 30% 61, have all been associated with worse 
outcomes, in TBI patients. 
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Effects of RBCT in TBI  
As mentioned beforehand, red blood cell transfusion is considered a life-saving procedure 
in critical care, due to its immediate effect of raising hemoglobin levels and, therefore, 
allowing the tissues’ metabolic needs to be met 58. However, data relating to RBCT and 
its effect in traumatic brain injury patients is limited and rather conflicting, mainly due to 
the methodological limitations of the studies conducted, such as their mostly retrospective 
nature, small sample sizes, and variation in outcome measures, that make the 
generalization of results to this patients’ population not viable nor scientifically correct. 
Therefore, several questions have been raised about the effects of RBCT in TBI:  
 
(1) What is the effect of RBCT in the brain’s oxygenation?  
By continuously measuring the PbtO2 in brain-injury patients, it has been showed that 
higher hemoglobin concentrations are linked to higher levels of PbtO2, and one 
observational study, conducted in 35 brain-injured patients, showed a mean increase in 
brain oxygenation by 49%, after RCBT 62, independent of changes in CPP. These post-
transfusion increments of PbtO2 were also documented in the majority of TBI patients 
(75%), and associated with a significant increase of Hb concentrations and lower baseline 
cerebral oxygenation 63. On the other hand, some studies have showed a decrease in brain 
oxygenation in up to 33% of such patients [70]–[72].  
Together with PbtO2, measuring the jugular venous oxygen saturation, or SjvO2, is one of 
the methods used for analyzing blood oxygenation after RBCT. One prospective study, 
in which post-transfusion SjvO2 was measured in 59 cases of severe TBI, showed a 
significant increase in SjvO2 after RBCT (p = 0.02), demonstrating the effect of RBCT 
in raising systemic oxygen delivery 66. 
Another factor that influences changes in brain oxygenation is the autoregulatory 
mechanisms of the brain itself. Autoregulation can be indirectly evaluated by calculating 
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the Pressure Reactivity Index, or PRx, a correlation coefficient between MAP (mean 
arterial pressure) and ICP (intra-cranial pressure) 67. Its values vary from -1 and +1, with 
positive values linked to impaired or absence of autoregulation, and, conversely, negative 
values indicating preserved autoregulation, which is associated with an improvement in 
PbtO2 68.  
An retrospective analysis, where 28 severe TBI patients were sub-divided in 2 groups 
based on their mean pre-transfusion PbtO2, showed that patients with higher brain 
oxygenation previous to RBCT (PbtO2 > 20 mmHg) had a significant increase in PRx, 
suggesting loss of autoregulation after transfusion, probably because they were not 
ischemic at baseline, or were in an oxygen-dependent state prior to transfusion. On the 
other hand, patients with pre-transfusion cerebral hypoxia (PbtO2 < 20 mmHg) had no 
significant changes in their PRx, equivalent to no changes in autoregulation, suggesting 
that RBCT does not deteriorate autoregulation in patients who already suffer from 
hypoxia. Despite major limitations, mainly the small sample size included, this study 
enlightens some of the doubt surrounding the effects of RBCT in TBI, as we can infer 
that patients with cerebral hypoxia are better candidates to transfusion, as they do not 
suffer from post-transfusion impaired cerebrovascular reactivity, and present significant 
improvements in cerebral oxygenation 69. 
NIRS, or near-infrared spectroscopy, is a technology used for brain monitoring since 1985 
70, and it allows intensivists to monitor the regional cerebral hemoglobin oxygen 
saturation (rSO2), a measure of the brain’s oxygenation status, with the minimum being 
set to 75% 71, as lower levels are associated to higher mortality and complication rates 72.  
One prospective study of 24 severe TBI patients used non-invasive monitoring of rSO2, 
using NIRS with bilateral frontal scalp probes, in order to assess this technology’s 
applicability in neurocritical patients subjected to RBCT, as well as to determine the 
correlation between rSO2 and other relevant physiological variables. 20 transfusions were 
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performed in 19 patients, 5 patients’ recordings were excluded due to poor signal quality. 
Hemoglobin concentrations increased significantly after transfusion, and rSO2 increased 
in most patients (87% and 81% for right- and left-side lobes, respectively), although this 
change did not occur in an significant manner, even after adjusting for potential 
confounders (p = 0,11 and p = 0,68, for right- and left-side lobes, respectively). No 
statistically significant correlations were found between changes in rSO2 and changes in 
other physiological variables. When measuring FTOE (fractional tissue oxygen 
extraction), they found higher post-transfusion FTOE in patients with lower pre-
transfusion Hb levels (Hb < 7g/dL), although this variation was not statistically 
significant. Also, FTOE decreased after transfusion, but also in a non-significant manner. 
Being the first study to assess changes in rSO2 after RBCT in TBI patients using NIRS 
technology, the authors attributed these non-significant changes in rSO2 to pre-
transfusion Hb levels not being low enough, or changes in Hb levels not being large 
enough to impact rSO2 significantly. Also, as cerebral autoregulation was not evaluated, 
they hypothesized impairment or loss of cerebral autoregulation to be the cause of such 
non-significant variations. Nevertheless, this novel method as several advantages over 
other neuro-monitoring methods (non-invasive, easy to use, minimal variability between 
operators), and takes in account a broader collecting of data from the brain’s cortex, 
allowing to evaluate both regional and global cerebral oxygenation. Therefore, NIRS 
measurement of rSO2 should be included in the decision process of transfusing TBI 
patients 73. 
Although a increase in tissue oxygenation has been showed after RBCT, it does not 
necessarily translate in a higher consumption and utilization of oxygen.  
For instance, PET imaging in aSAH patients 74, has shown that transfusions lead to 
significantly higher global oxygen delivery, reducing the number of low-delivery areas 
by 50%, with maximum effect in oligemic areas (highest risk of ischemia), without 
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affecting the CMRO2. Also, the resultant increase in blood viscosity, secondary to RBCT, 
did not decrease cerebral blood flow significantly, a main concern in previous studies, as 
loss of autoregulation did not allow normal vasoconstriction, in response to a higher 
arterial content of oxygen. Importantly, transfusion was also able to reduce the oxygen 
extraction fraction (OEF), raised in the context of anemia, thus increasing cerebrovascular 
reserve, and the brain’s resistance to additional ischemic injury 74.  
Some authors have proposed that blood viscosity should be a transfusion trigger 75. In 
fact, anemia leads to low blood viscosity, to which the microvascular system responds 
through vasoconstriction, with decrease of blood flow and in the percentage of open 
capillaries, resulting in lower functional capillary density (FCD). RBCT can help in the 
normalization of FCD through 2 mechanisms: by raising blood viscosity, resulting 
increase in shear stress results in the releasing of vasodilating substances from the micro-
vessels, such as nitric oxide and ATP 76; by raising hemoglobin concentrations, this 
molecule functions as oxygen sensor, leading to additional releasing of the same 
vasodilating substances, consequently raising blood flow and oxygen delivery 20. 
Finally, other factors, such as age and gender, should also been taken in account. 
Arellano-Orden et al. have shown that women and younger individuals victims of severe 
TBI, have significantly higher increments in PbtO2 after transfusion of red blood cells 77. 
 
(2) What is the effect of RBCT on the brain’s metabolism? 
Cerebral microdyalisate studies have mostly shown that, although red blood transfusions 
improve brain oxygenation, they appear to have little to no effect in the brain’s 
metabolism. Has mentioned previously, lactate:pyruvate ratios (LPR) can be measured in 
the cerebrospinal fluid, and compared to assess the effects of RBCT, with values over 25 
being indicative of tissue ischemia.  
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Zygun et al., in a clinical study of 30 severe TBI patients 65, observed a increase of LPR 
in 56% of individuals, and no significant change in cerebral pH. Also, no significant 
correlation was found between hemoglobin concentrations’ and LPR’s variations (p = 
0,76), but posterior analysis revealed a significant association between these two 
variables and the prediction of PbtO2 change (p = 0,023). If baseline LPR was under 25, 
there was no significant association, but, for patients with higher exposure time to anoxia 
(baseline LPR above 25), an increase of 1 g/dL of Hb concentrations was associated with 
a significant increase of 0,18 kPa of PbtO2. This 2009 study was the first to study the 
effects of RBCT in cerebral metabolic markers, and found no benefits of RBCT to the 
brain’s metabolism 65. Another more recent study into SAH patients 78 also demonstrated 
no significant changes in LPR after RBCT, and no significant association between 
variations of Hb concentrations and LPR.  
Unfortunately, no studies of this nature have yet to be conducted in TBI patients. 
 
(3) Does the storage age of RBC’s influence the effects of this therapy? 
In recent years, concern been raised about the effect of the storage age of red blood cells 
on their oxygen-transporting ability, and the irreversible changes that occur during 
storage and how they affect clinical outcomes in transfused patients.  
First of all, RBC’s can be stored in liquid mediums for up to a maximum period of 35 to 
42 days, with a mean age of 2-4 weeks for units transfused in the ICU 39. The so-called 
“storage lesion” includes a diversity of physical and metabolic irreversible changes, 
whose magnitude increases with longer storage times, including 79:  
• lower pH, with resulting acidosis, which endangers the survival and metabolic 
pathways of red blood cells; 
• reduction of ATP, due to blockage of glycolysis, with less energy available for the 
cell’s metabolism; 
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• reduction of 2,3-DPG (2,3-diphosphoglycerate) concentrations, with less NADH 
(nicotinamide adenine dinucleotide reducing equivalents) production, lower met-
hemoglobin reductase activity and, consequently, higher concentrations of met-
hemoglobin (biologically inactive), jeopardizing the RBC’s oxygen delivery capacity; 
• accumulation of extra-cellular potassium, with higher risk of potentially lethal 
arrhythmias; 
• membrane loss, with concomitant increase of plasma-free hemoglobin, which binds 
to endothelial nitric oxide, inducing inappropriate vasoconstriction; 
• membrane deformities, which may compromise microvascular circulation and elevate 
the risk for microthrombosis;  
• oxidative injury to membrane proteins, decreasing the integrity of the cell’s 
cytoskeleton and creating neo-antigens;  
• oxidative injury to phospholipids with formation of biologically active metabolites, 
increasing the risk of TRALI;  
• loss of carbohydrates from the membrane leads to the increase of cell adhesion to the 
vessel’s wall;  
• bacterial contamination, which can cause septic shock.  
 
Also, leucocytes, which are stored with red blood cells in whole blood, produce cytokines 
and other pro-inflammatory substances that can potentiate the RBC’s storage damage, 
such as an increase in cell adhesion to the vascular endothelium 80. These 
immunomodulatory mechanisms are less well understood, but still have led to 
recommending universal leukoreduction, in order to reduce transfusion-related 
complications, with controversial results 81,82. 
In order to understand the effect of storage age of RBC’s in critical care, and specifically 
in traumatic brain injury patients, several studies have been conducted, with controversial 
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results. It was, firstly, hypothesized that “fresher than usual” blood, compared to the 
standard of 20-25 days of storage age, would present less storage lesion and, therefore, 
lead to fewer complications.  
The ABLE trial (Age of Transfused Blood in Critically Ill Patients) 83, a multicenter, 
randomized, blinded trial, conducted in 64 centers in Canada and Europe, studied the 
effects of “standard” versus “fresher” red blood cell units in 2413 patients, randomly 
allocated to one of the treatment arms. They concluded that there was no benefit in 
transfusing “fresher than usual” RBC’s, as both primary outcomes (90-day all-cause 
mortality) and secondary outcomes (organ dysfunction, infection rates, length of stay in 
ICU and hospital settings, duration of organic support, adverse events and transfusion 
reactions) were similar in both groups. These results were consistent with the results from 
other previous clinical trials (84,85), and were not consistent with older observational 
studies that associated longer age of storage of RBC’s to harmful effects (80,86,87). 
In TBI, Yamal et al. showed no significant differences in brain oxygenation, long-term 
neurologic deficits and mortality between 200 severe TBI patients randomly assigned to 
receive “older”(≥ 14 days) versus “younger” (<14 days) RBC units 66, and Weinberg et 
al., in a trial of 1647 trauma patients, determined that the age of RBC units was not 
associated to a higher mortality risk 88. 
Therefore, we can conclude that RBC units with age storage shorter than standard 
recommendations does not present significant benefits for critical care patients, including 
TBI patients, and that blood banks should follow the same recommendations for 
transfusion of critically ill patients in TBI cases, according to the age of storage.  
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(4) What is the effect of RBCT in clinical outcomes in TBI patients?  
Besides mortality, neurological outcome scores are one of the main short and long-term 
outcome measures assessed in traumatic brain injury patients, as TBI is one of the major 
causes of long-term disability worldwide 89.  
Patients who suffer TBI are more prone to develop permanent disabilities, with 35% of 
the survivors suffering from significant long-term neurological deficits 8, and 52% living 
with moderate to severe disabilities after a 1-year follow-up 90.  
In order to assess long-term neurological outcomes in TBI patients, multiple scales have 
developed and widely used 91, the main being: the Glasgow Outcome Scale (GOS) 92, the 
Rancho Los Amigos Levels of Cognitive Functioning Scale (RLCFS)93, and the 
Disability Rating Scale (DRS) 94. 
Leal-Noval et al., in a 3-year prospective study of RBCT’s association with neurological 
outcomes scores, in 309 TBI patients admitted to the neurological intensive care unit 95, 
used these three scales to evaluate neurocognitive and disability levels at a 1 year follow-
up, and concluded that patients who received blood transfusions (53% of the study’s 
population) had significantly higher rates of unfavorable neurological scores at 6- and 12-
months follow-up. This patient subgroup also a presented significantly longer stay in 
neurocritical care units, and a higher hospital mortality rate ( p < 0.01). Although this 
study’s results contradicted the findings from previous studies (96,97), it provided valuable 
information due to its strengths, as being the largest study to date to investigate this 
association, and the first to apply different statistical methods in analyzing the same 
association. 
Based on these conclusions, the authors advised practicians and intensivists to exert 
caution when giving RBCT’s in TBI patients, due to the study’s limitations. 
 
Previous to the publication of the TRICC trial (Transfusion Requirements in Critical 
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Care) in 1999, the common practice was that red blood cell transfusion (RBCT) was 
recommended for general care and ICU patients who were diagnosed with anemia and 
whom hemoglobin concentrations were lower than 10 g/dL 98. This “liberal” approach 
was compared to a more conservative / “restrictive” approach (only performing RBCT if 
hemoglobin concentrations lower than 7 g/dL) in the TRICC trial, by randomizing 838 
critically ill patients with isovolemic anemia 25.  
 
The results of this trial included:  
• The base-line characteristics were similar between the two treatment groups;  
• Patients who were not enrolled, due to exclusion criteria, refusal to consent or 
withdraw from the trial, were slightly older (p = 0.04) and had a lower percentage 
of cardiac disease (p < 0.01) as their primary diagnoses, but there were no 
significant differences in the remaining primary diagnoses (p = 0.26) nor in the 
disease severity (APACHE II scores were similar, p = 0.36). 
• Patients randomized for the restrictive-strategy group, due to the lower threshold 
used, had relatively less 54 percent transfusions, and 33 percent did not receive 
any transfusion, while every patient in the liberal-strategy group received at least 
one unit of RBC during the trial. 
• There were no differences in the primary outcome, which was the rate of death 
from all causes in the first 30 days after admission, and mortality during 
hospitalization (compared to mortality at 60 days or in the ICU) was actually 
significantly lower in the restrictive group.  
• During subgroup analyses, two groups stood out from the others, due to a 
significantly lower mortality in the restrictive strategy patients: patients younger 
than 55 years (p = 0.03), and patients with a lower disease severity (APACHE II 
score ≤ 20 points, p = 0.02). 
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• After adjustment for possible confounders, multiple organ-dysfunction scores 
were significantly higher in the liberal-strategy group (p = 0.03), and, compared 
to the baseline score, changes in these scores were significantly higher in the same 
group (p = 0.04). The liberal group also experienced a significantly higher 
percentage of cardiac complications (p < 0.01), specifically myocardial infarction 
(p = 0.02) and pulmonary edema (p < 0.01). 
 
Thanks to the results of the TRICC trial, red blood cell transfusion practices changed 
forever in both the general and intensive care units. Although previous similar trials and 
studies had been conducted on this subject (26,99–102), the populations studied in these trials 
were rather small or too specific, making it difficult to generalize results for the majority 
of critically ill patients. 
Therefore, it is safe to recommend the use of an hemoglobin concentration threshold as 
low as 7.0 g/dL in ICU units, while maintaining such concentrations in a range of 7.0 to 
9.0 g/dL, as this strategy is at least as effective and possibly superior to a more liberal 
transfusion strategy (with a threshold of 10.0 g/dL, and a maintenance range of 10.0 to 
12.0 g/dL) 25.  
At the time, no large randomized controlled trial had been conducted in the traumatic 
brain injury population, reason why clinicians and intensivists were still fearsome and 
cautious in the application of this findings in this type of patients. 
Since then, various studies have analyzed the effects of this restrictive strategy in TBI 
patients.  
 
Several retrospective studies 61,103,104 have shown that RCBT was not associated with 
worse outcomes in TBI patients, compared with patients who did not receive transfusions. 
Salim et al. 60 conducted a retrospective study on blunt trauma patients with TBI, in which 
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both anemia and blood transfusion, when analyzed separately, were associated to a higher 
mortality and complications’ risk, but when this two patient’s characteristics were 
combined, RBCT was associated to worse outcomes, but anemia was not. Duane et al. 
105, in their own retrospective review of 788 TBI patients, also associated blood 
transfusions with worse outcomes, but believe there is a dose-dependent effect, as non-
survivors had received higher numbers of blood products, although they also considered 
the need to transfuse, due to the patient’s critical condition, a confounder between 
mortality factors.  
 
The ABC (Anemia and Blood Transfusion in Critically Ill Patients)106, and SOAP (Sepsis 
Occurrence in Acutely Ill Patients)96 trials, conducted in adult ICU patients, showed 
similar results to the TRICC trial, with no significant association found between RBCT 
and worse outcomes. McIntyre et al. 107, in a subgroup analysis of the TRICC trial 
conducted in 2006, studied 67 patients with TBI, and found no significant differences 
between the restrictive and liberal threshold groups, in terms of 30-day mortality (p = 
0,64), ICU (p = 0,26) and hospital length of stay (p =  0,72), and multi-organic 
dysfunction (p = 0,35). A randomized clinical trial on the effects of erythropoietin (EPO) 
and two different transfusion thresholds (7 and 10 g/dL) 108, performed in 200 closed head 
injury patients, showed no interaction between EPO and hemoglobin thresholds, no 
benefit in EPO treatment, and a higher adverse events rate in the 10 g/dL threshold group, 
mainly thromboembolic events. Therefore, no evidence was found to support a liberal 
approach to transfusion.  
 
Studies done in critical pediatric care populations have also shown little benefit in liberal 
transfusion strategies. In the TRIPICU (Transfusion Requirements in the Pediatric 
Intensive Care Unit) trial, 637 stable, but critically ill children, presenting anemia (Hb < 
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9,5 g/dL) in the first seven days within admission, were randomly assigned a restrictive 
or liberal transfusion threshold (7 g/dL, or 9,5 g/dL, respectively). Children in the 
restrictive group received 44% fewer transfusions, with 54% receiving no transfusion at 
all, compared with only 2% of the children in the liberal group. No significant differences 
in multi-organ dysfunction, mortality and other adverse outcomes were found, between 
the two groups, rendering restrictive transfusion practices safe for pediatric ICU patients. 
The same was verified in a latter subgroup analysis of 66 children that suffered any form 
of brain injury 109. In opposition, Bell et al. conducted a randomized clinical trial 
comparing two different transfusion thresholds based on hematocrit levels (restrictive 
versus liberal methods), enrolling 100 preterm infants. Infants in the restrictive group 
received less transfusions, but had more adverse side effects, mainly intraparenchymal 
brain hemorrhage, periventricular leukomalacia and more frequent episodes of apnea 
(both mild and severe), making the restrictive approach to RBCT not suitable for preterm 
infants 110. Another trial, conducted in 441 extremely low birth weight infants (<1000 
grams), comparing low and high hemoglobin thresholds for transfusion, found that, 
although infants in the low threshold group received significantly fewer transfusions (p = 
0,037), outcomes were similar, showing little to no benefit in maintaining higher levels 
of hemoglobin concentration 111. 
 
In order to understand how clinicians apply guidelines and evidence-based 
recommendations in their day-to-day practice, two surveys were performed in North 
America. More than half of the practicians questioned responded to the surveys. One 
survey’s purpose 112 was to determine the hemoglobin threshold used by doctors from 3 
different specialties, in 2 different clinical scenarios of TBI, where one presented with 
intracranial hypertension, and the other did not. Depending on specialties, variability in 
used thresholds was observed, with neurosurgeons using higher mean thresholds, 
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independently of intracranial pressure, being less considering of the immunodulatory 
effects of RBCT, and relying less in indicators of anemia intolerance. Apart from these 
disparities, all groups believed that secondary ischemic injury was a main concern after 
TBI. The other survey 113 assessed common triggers used by practicians in the 
administration of blood transfusions in SAH patients. Once again, variability in responses 
was significant, with more liberal goals of hemoglobin concentrations for patients with 
high-grade SAH or delayed cerebral ischemia (DCI), while restrictive thresholds were 
preferred in low-grade SAH. Neurosurgeons continue to prefer higher minimum Hb 
levels, and transfusion of more RBC units, when compared to intensivists. The existence 
of protocols based in guidelines was associated to more restrictive thresholds, advanced 
seniority was correlated to higher Hb goals, and practicians were more comfortable with 
transfusing patients if they presented objective signs of cerebral ischemia (PbtO2 < 15 
mmHg, and LPR > 40). 
 
Reviews on transfusion practices in acute brain injury highlight the clinical equipoise 
affecting this theme, as evidence is, sometimes, contradictory. It is still essential to 
determine if anemia and the need to transfuse are consequences of the disease itself, or 
independent indicators of outcome 3. Also, although restrictive transfusion thresholds 
have been objectively considered as safe as liberal methods, practicians still consider TBI 
patients to be particularly sensitive to anemia, reason why more liberal thresholds are, in 
real life clinical scenarios, implemented in these patients, especially in symptomatic 
anemia 114. 
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CURRENT GUIDELINES 
When analyzing the multiple guidelines who handle the treatment and management of 
ICU patients and specifically neurocritically ill patients, including TBI patients, there is 
a lack of strong evidence-supported recommendations and even, at times, a complete 
absence of red blood cell transfusion referral as a mean of treating these patients.  
The American Heart Association/American Stroke Association (AHA/ASA) guidelines 
include a recommendation for the use of packed red blood cell transfusion (RBCT) for 
treating anemic patients who are at risk of cerebral ischemia, in case they suffer from 
aneurysmal subarachnoid hemorrhage (aSAH) 115, but the optimal hemoglobin goal is not 
defined, due to the lack of evidence (class IIb, level B). Although those guidelines were 
published 2012 and may be, therefore, outdated, they are still more informative than the 
guidelines for spontaneous intracerebral hemorrhage (ICH) 116 or acute ischemic stroke 
(AIS) 117, which were published in 2015 and 2018, respectively, and do not make any 
reference to RBCT. The same occurs with Traumatic Brain Injury, where even the most 
recent guidelines from the Brain Trauma Foundation 44, published in 2016, do not 
included RBCT in their treatment plan.  
The American Academy of Neurology (ANN) has published guidelines informing 
practicians how to handle specific situations related to TBI, as antiepileptic drug 
prophylaxis 118 and reducing brain injury after cardiopulmonary resuscitation 119, but not 
about TBI itself or the role of RBCT in these patients.  
The Congress of Neurological Surgeons (CNS) did publish guidelines about the acute 
medical treatment of TBI, but only specifically for pediatric patients, without making any 
reference to RBCT 120. 
Although this two specialists’ societies have not directly published guidelines referring 
to red blood cell transfusion as a treatment tool for TBI patients, they have, conjointly 
with the American Association of Neurological Surgeons (AANS), taken part in the 
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development of other neurological pathological entities’ guidelines, including the Brain 
Trauma Foundation’s Guidelines for TBI, which, as referred previously, does not handle 
the subject of RBCT in this patient subgroup. 
On the other hand, societies more related to blood transfusions themselves and treatment 
of ICU patients have published guidelines and articles about the thresholds that should be 
used when transfusing TBI patients. The American Society of Anesthesiologists (ASA) 
defends a restrictive strategy for red blood cell transfusion in all patients, if hemoglobin 
levels are lower than 8 g/dL and hematocrit is lower than 25%, arguing that RCT’s done 
on the issue show similar length of hospital stay, mortality and complication rates, and a 
lower need of transfusions (according to meta-analysys of RCT’s), when compared to the 
previously advocated liberal strategy 121. The American Association of Blood Banks 
(AABB) equally recommends a restrictive RCBT threshold in which transfusion should 
be given to hospitalized adult patients (including ICU patients) who suffer from anemia 
and whose hemoglobin levels are under 7 g/dL, excluding patients who have been 
diagnosed with acute coronary syndrome, severe thrombocytopenia or chronic 
transfusion-dependent anemia. However, a threshold of 8 g/dL should be considered for 
patients who have preexisting cardiovascular disease, or are undergoing orthopedic or 
cardiac surgery. Also, RBC units should not be limited to fresh blood, any age of storage 
can be selected, as long as it is within the licensed dating period 122. 
Also, the American College of Surgeons Trauma Quality Improvement Program (ACS 
TQIP) published a “best practices” guideline for TBI management, in which they 
highlight the importance of closely monitoring anemia and coagulopathy, as they are 
commom in TBI patients. The restrictive strategy for transfusion (Hb threshold of  7g/dL) 
is recommend, based on recent randomized clinical trial’s results, which, as in the TRICC 
trial, showed no significant differences in neurological outcomes, and a higher percentage 
of adverse outcomes in the liberal strategy, when comparing the two treatment methods.  
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Nowadays, the most complete guidelines about the treatment of anemia in critically ill 
patients are provided by the British Committee for Standards in Haematology 39. They 
make evidence-based recommendations for each subtype of brain injury, for other diverse 
clinical entities that may require blood transfusions, but also tackle ways of reducing 
transfusion requirements and how to treat specific complications of transfusion. Table 1 
(see in Supplementary Material) resumes the recommendations for patients in 
neurocritical care. 
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Ongoing Studies 
There are two ongoing randomized trials being conducted on the optimal transfusion 
threshold for TBI patients: the Transfusion Strategies in Acute Brain Injured 
Patients/TRAIN trial (NCT02968654), and the Hemoglobin Transfusion Threshold in 
Traumatic Brain Injury Optimization/HEMOTION trial (NCT03260478).  
The TRAIN trial (2016-2021) is a prospective, multicenter, randomized, pragmatic trial, 
that will enroll 4610 participants suffering from acute brain injury (including TBI, SAH 
and ICH patients), and randomly assigned them to either a restrictive or liberal transfusion 
threshold (<7 g/dL, and <9 g/dL, respectively). The primary outcome will be a good 
neurological outcome at 180 days after randomization, defined by an extended Glasgow 
Outcome Score (eGOS) of 6-8, while secondary outcomes will include various variables, 
including survival, changes in Glasgow Coma Score (GCS), ICU and hospital length of 
stay, multi-organic dysfunction, infection rate, brain oxygen pressure (PbtO2), and serious 
adverse events to transfusion.  
At the same time, the HEMOTION trial (2017-2021) will enroll less patients (712), but 
will exclusively enroll severe blunt TBI patients, with GCS ≤ 12 points and anemia 
(defined as Hb ≤ 10 g/dL). These patients will, as in the previous trial, be randomly 
assigned a restrictive or liberal transfusion threshold (in this case, ≤ 70 g/L, and ≤ 100 
g/L, respectively). The primary outcome will be the same as in the TRAIN trial, with 
secondary outcomes including mortality at 6 months, patient function, overall and TBI-
specific quality of life, depression, return to day life activities, and transfusion-related 
complications. 
We hope the results from these trials will contribute to enlarge the quality of evidence 
about the effects of transfusion in TBI patients, and to strengthen recommendations for 
transfusion practices in these patients.  
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Daily Practice Considerations 
As both anemia and blood transfusion have been both inconsistently associated with 
worse outcomes in TBI, and the effects of RBCT in brain oxygenation are controversial, 
a “blood transfusion anemia paradox” has been the cornerstone for lack of high-quality 
evidence-based recommendations in managing anemia in TBI patients.  
In light of all the evidence available about the use of different transfusion triggers in acute 
neurologic pathological states, a recent review 123 has developed a “practical approach” 
for treating anemia in ABI, that can be extrapolated for TBI patients. 
Through complete neurological examination, patients should be immediately classified 
in awake-conscious or poor-grade individuals, based in neurological findings/deficits and 
neurologic status classification scores, e.g., a Glasgow Coma Scale (GCS) score lower 
than 8 points (coma) should be considered a poor-grade status.  
After that, and according with the recommendations for general ICU patients, patients 
with brain injury and a good neurological status should be submitted to “restrictive” 
transfusion practices and repeated clinical surveillance, in order to assess immediate and 
short-term effects of transfusion, including adverse effects, as well as treatment of other 
potentially life-threating conditions. 
In case of patients with baseline poor neurological status or with rapid deterioration of 
such, the decision to transfuse should be individualized and based in both “systemic” and 
“cerebral” triggers.  
“Systemic” triggers should focus on the mixed or superior venous cava oxygen saturation 
(SvO2 or ScvO2) and blood lactate levels. SvO2 or ScvO2 > 70% is considered a marker 
of oxygen delivery optimization, and can be achieved through various treatments, from 
positive pressure ventilation to RBCT, as shown in the SOAP trial 96. Also, is has been 
demonstrated that achieving an ScvO2 > 65% after anoxic brain damage can reduce 
mortality 124 and improve neurological outcomes 125. Normalizing systemic lactate levels 
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is also one the goals of intensive care practicians 126, as lactic acidosis is a marker of tissue 
ischemia and hypoperfusion, and, as other acid-base abnormalities, is associated to a 
higher risk of multi-organic dysfunction and death 127. RBCT should, therefore, only be 
considered if these “systemic” markers of tissue hypoxia are abnormal. 
“Cerebral” triggers, on the other hand, refer to brain oxygenation markers, such as PbtO2, 
rSO2 and jugular venous saturation (SjvO2). Patients with PbtO2 < 15-20 mmHg and SjvO2 
< 55% are at high-risk of secondary brain damage, as these are indicators of cerebral 
hypoxia51, which can be caused either by low systemic oxygen delivery or, in the case of 
normal DO2, due to other causes of cerebral hypoperfusion.  
Practicians should, firstly, guarantee a good systemic vascular support for oxygen 
delivery to the brain, by treating systemic infirmities (such as systemic hypotension, 
hypoxemia, hyperthermia), and, if low cerebral perfusion remains a concern, rule out 
organ-specific causes for this issue (such as severe hypocapnia or intracranial 
hypertension). In this case, RBCT can be considered in patients with normal DO2 and 
cerebral hypoxia signs, and should always be considered in patients with low systemic 
and cerebral oxygen delivery.  
The choice to transfuse in TBI patients continues to represent a clinical challenge for 
intensivists, even in the presence of highly advanced neuromonitoring tools and 
technological resources for treating systemic maladies. 
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Conclusion 
The lack of consistency in data related to anemia, blood transfusions and their effects in 
traumatic brain injury patients, cannot allow practicians to create safe and strong 
evidence-based protocols for the treatment of such patients, and do not permit the 
establishment of specific transfusion triggers in common practice.  
While we await the results from RCT’s and other studies dealing with the issue, red blood 
cell transfusions, as in all other blood products, should be carried out in an individualized 
and precautious manner, taking in account various variables indicative of the patient’s 
status.  
More randomized controlled trials, with bigger populations, should be a major priority in 
intensive care, in order to unravel the present imprecisions in this issue.     
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Supplementary Material 
 
Table 1: Target hemoglobin values for patients with acute neurologic injury. TBI, 
Traumatic Brain Injury; AIS, Acute Ischemic Stroke; SAH, Subarachnoid Hemorrhage; 
ICU, Intensive Care Unit  
 
7-9 g/dL
• TBI
> 9 g/dL
• TBI and 
evidence of 
cerebral 
ischemia
• AIS (in ICU)
8-10 g/dL
• SAH
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number of tables and  gures, a short running title, and three to six keywords to index the content.
When submitting the manuscript online, provide the names, a liations, and email addresses of three
preferred reviewers at institutions other than those of the authors.
The total number of words in the text, as well as the number of  gures and tables should be listed at the
bottom of the title page.
Authors are encouraged to check for an existing account. If you are submitting for the  rst time, and you
do not have an existing account, then you must create a new account. Once you have logged in, you will
be presented with the Main Menu and a link to your Author Center. Submit your manuscript from the
Author Center. At the end of a successful submission, a con rmation screen with a manuscript number
will appear, and you will receive an e-mail con rming that the manuscript has been received by the
13/03/2019 American Journal of Hematology
https://onlinelibrary.wiley.com/page/journal/10968652/homepage/forauthors.html 2/8
journal. If this does not happen, please check your submission and/or contact our Help Desk
at AJHadmin@wiley.com.
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John Wiley & Sons 
111 River Street 
Hoboken, NJ 07030 
E-mail: AJHadmin@wiley.com
Editor in Chief: 
Carlo Brugnara, MD 
Department of Laboratory Medicine, 
Children’s Hospital Boston 
300 Longwood Avenue, BA 760 
Boston, MA 02115, USA 
Phone: 617.355.6610 
Fax: 617.730.0383 
e-mail: Carlo.Brugnara@childrens.harvard.edu
Submission Requirements
All manuscripts submitted to the American Journal of Hematology must be submitted solely to this journal.
Submissions may not have been published in any part or form in another publication of any type,
professional or lay, or become the property of another publisher. Any material reproduced or adapted
from any other published or unpublished source must be duly acknowledged. It is the author's
responsibility to obtain permission to reproduce copyrighted material. Upon submission of a manuscript
for publication, the author will be requested to sign an agreement transferring copyright to the publisher,
who reserves copyright. Material published in this journal may not be reproduced or published elsewhere
without the written permission of the publisher and the author. All statements in, or omissions from,
published manuscripts are the responsibility of the author who will assist the editor and publisher by
reviewing proofs. No page charges will be levied against authors or their institutions for publication in this
journal.
All authors should have contributed in a signi cant manner and be in agreement with all content in a
manuscript. The corresponding author will take responsibility for upholding this requirement.
Wiley suggests that authors from non-English speaking countries have their manuscript reviewed and
corrected by English Language Services before submission. Please see the following link from Wiley-
Blackwell as we have adopted their policy:
http://authorservices.wiley.com/bauthor/english_language.asp.
By submitting a manuscript to or reviewing for this publication, your name, email address, and a liation,
and other contact details the publication might require, will be used for the regular operations of the
publication, including, when necessary, sharing with the publisher (Wiley) and partners for production
and publication. The publication and the publisher recognize the importance of protecting the personal
information collected from users in the operation of these services, and have practices in place to ensure
that steps are taken to maintain the security, integrity, and privacy of the personal data collected and
processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-
policy.html.
REVIEW PROCESS
Manuscripts are usually assigned to one of the Associate Editors. Every submitted manuscript will
undergo a rapid in-house review to determine if it is suitable for the journal and if it has priority ranking in
relationship to all other manuscript being considered for publication that would justify a review by
external experts. Manuscripts will be rejected without external review if they are deemed not suitable for
the journal or if they have low priority ranking. Manuscripts are usually sent out for review to at least two
external, expert reviewers. AJH will try to follow authors’ suggestions for possible inclusion or exclusion of
speci c experts in the  eld. Authors will receive e-mail noti cation concerning the  nal editorial decision,
with comments from reviewers and editors when applicable.
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RAPID REVIEW OF MANUSCRIPTS SUBMITTED PREVIOUSLY TO ANOTHER JOURNAL: 
As stated in the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and
Editing for Biomedical Publication” ( http://www.icmje.org ; Updated February 2006): “ If the manuscript
has been submitted previously to another journal, it is helpful to include the previous editor’s and reviewers’
comments with the submitted manuscript, along with the authors’ responses to those comments. Editors
encourage authors to submit these previous communications and doing so may expedite the review process .”
For manuscripts previously submitted to other journals with impact factor more than 8 , if authors
include previous editor’s and reviewers’ comments along with their responses, the American Journal of
Hematology will guarantee a rapid (within a week) in-house assessment, with three possible outcomes: 
a) Acceptance or acceptance with minor changes (no additional external reviews needed); 
b) Rejection; 
c) Additional external review needed; in this case the authors will have the possibility of accepting the
additional external review or withdrawing the manuscript. 
d) When submitting a paper for Rapid Review, upload a Word document containing the previous
review comments and your responses as “Supplementary Material for Review." After submitting
the manuscript, please e-mail the editorial o ce at ajhadmin@wiley.com along with your
assigned manuscript number (AJH-XX-XXXX) to alert the editorial o ce to your submission.
If your paper is accepted, the author identi ed as the formal corresponding author for the paper will
receive an email prompting them to login into Author Services; where via the Wiley Author Licensing
Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.
For authors signing the copyright transfer agreement
If the OnlineOpen option is not selected the corresponding author will be presented with the copyright
transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples
associated with the Copyright FAQs below:
CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp
For authors choosing OnlineOpen
If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative
Commons License Open Access Agreements (OAA):
Creative Commons Attribution Non-Commercial License OAA
Creative Commons Attribution Non-Commercial -NoDerivs License OAA
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs
hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit
http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.
If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of
the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY
license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For
more information on this policy and the Journal’s compliant self-archiving policy please visit:
http://www.wiley.com/go/funderstatement.
For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this
license:
Creative Commons Attribution License OAA
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs
hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit
http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.
DISCLOSURE STATEMENT. All authors must disclose any a liations that they consider to be relevant and
important with any organization that to any author's knowledge has a direct interest, particularly a
 nancial interest, in the subject matter discussed. Such a liations include, but are not limited to,
employment by an industrial entity, ownership of stock, membership on a standing advisory council or
committee, a seat on the board of directors, or being publicly associated with a company or its products.
Other areas of real or perceived con ict of interest would include receiving honoraria or consulting fees
or receiving grants or funds from corporations or individuals representing such corporations. This
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requirement will apply to every sort of article submitted to the Journal , including original research,
reviews, editorials, letters to the editor, and any others, and should be disclosed at the time of
submission. The simplest remedy for con ict of interest is disclosure. In the Journal , disclosure will
henceforth be achieved by the inclusion of a short footnote with each published article. This information
will be held in con dence while the paper is under review. It will not be shared with peer reviewers, and it
will not in uence the editorial decision to accept or reject the manuscript. When an article is accepted for
publication, the editors will usually discuss with the authors the manner in which such information is to
be presented.
RESEARCH ARTICLES. Articles should represent original and in-depth studies involving all aspects of
clinical or laboratory investigations. While there is no length restriction for articles, authors are
encouraged to limit the text to a maximum length of 5,000 words and references to no more than 100.
The number of illustrations and tables should be appropriate for the data presented, but should not
repeat information in the text.
The title page should contain the complete title of the manuscript, the names, degrees, and a liations of
all authors as well as the name, address, phone, fax and email of the person to whom all correspondence
should be addressed. While the number of authors should usually not exceed six, exceptions will be
granted with adequate justi cation. The title page should also include the abstract word count, text word
count, the number of tables and  gures, a short running title, and three to six keywords to index the
content.
Abstract. This should be a factual condensation of the entire work, including a statement of its purpose, a
clear description of the  ndings, including numbers, and  nally a concise presentation of the conclusions.
The abstract may not exceed 250 words.
Text. The text should follow the following format: Introduction, Methods, Results, and Discussion
(please note that this has been recently changed so that Methods is at the top of the paper, placed
in between Introduction and Results). Place Acknowledgments as the last element of the text, before
references. Use subheadings and paragraph titles when possible. Authors whose  rst language is not
English should arrange for their manuscripts to be written in idiomatic English and reviewed prior to
submission by an editor facile in medical English. This will avoid disappointing delays before a paper can
be sent out for review. Please see the "Submission requirements" section above for guidelines relating to
language.
Patients should be referred to only by subject numbers and not with names, initials, or other potentially
identifying characters. Manuscripts reporting the results of experimental investigations on human
subjects must include a statement to the e ect that the procedures received o cial institutional
approval.
Use non-capitalized generic names (e.g., cyclophosphamide) for all drugs and pharmaceutical
preparations. Trade names (capitalized) for appliances, etc., may be used in the Methods section, and the
manufacturers should be identi ed by name and address.
Any tables submitted with the text should be sent/uploaded as separate Word  les.
References: All references should be numbered consecutively in order of appearance and should be as
complete as possible. In text citations should cite references in consecutive order using Arabic superscript
numerals. Sample references follow:
Journal article:
1. King VM, Armstrong DM, Apps R, Trott JR. Numerical aspects of pontine, lateral reticular, and inferior
olivary projections to two paravermal cortical zones of the cat cerebellum. J Comp Neurol 1998;390:537-
551.
Book:
2. Voet D, Voet JG. Biochemistry. New York: John Wiley & Sons; 1990. 1223 p.
Please note that journal title abbreviations should conform to the practices of Chemical Abstracts.
For more information about AMA – American Medical Association reference style - AMA Manual of Style
Wiley's Journal Styles are Now in Endnote. EndNote is a software product that we recommend to our
journal authors to help simplify and streamline the research process. Using EndNote's bibliographic
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management tools, you can search bibliographic databases, build and organize your reference collection,
and then instantly output your bibliography in any Wiley reference style. If you already use EndNote, you
can download the reference style for this journal. How to Order: To learn more about EndNote, or to
purchase your own copy, click here .
Technical Support: If you need assistance using EndNote, contact endnote@isiresearchsoft.com , or visit
http://www.endnote.com/support .
Video Abstracts: A video abstract can be a quick way to make the message of your research accessible to
a much larger audience. Wiley and its partner Research Square o er a service of professionally produced
video abstracts, available to authors of articles accepted in this journal. You can learn more about it, and
purchase one for your article, at http://www.wileyauthors.com/videoabstracts . If you have any
questions, please direct them to videoabstracts@wiley.com .
Manuscript: For optimal production, prepare manuscript text using Microsoft Word. Please note: This
journal does not accept Microsoft WORD 2007 documents at this time. Please use WORD’s “Save As”
option to save your document as an older (.doc)  le type.
Figures: When preparing digital art, please submit your  gures and tables as separate  les and consider
the following:
Resolution:
The minimum requirements for resolution are:
1200 DPI/PPI for black and white images, such as line drawings or graphs.
300 DPI/PPI for picture-only photographs
600 DPI/PPI for photographs containing pictures and line elements, i.e., text labels, thin lines,
arrows.
These resolutions refer to the output size of the  le; if you anticipate that your images will be enlarged or
reduced, resolutions should be adjusted accordingly.
Formats:
For the entire submission/acceptance process, EPS or TIFF  les will be required. For the editorial review
process, color images may be submitted in RGB color; upon acceptance, CMYK color will be required.
Delivery of production-quality  les early in the review process may help facilitate smooth and rapid
publication once a manuscript has been accepted.
A legend must be provided for each illustration and must de ne all abbreviations used therein. Legends
should be placed at the end of the manuscript text  le or below each  gure. Please be sure to submit
your  gures and tables as separate  les.
Authors are encouraged to submit color illustrations that highlight the text and convey essential scienti c
information. All color  gures will be reproduced in full color in the online edition of the journal at no cost
to authors. Authors are requested to pay the cost of reproducing color  gures in print. For best
reproduction, use bright, clear colors. Dark colors against a dark background do not reproduce well;
please place your color images against a white background wherever possible. Please contact
ajhprod@wiley.com for further information.
CRITICAL REVIEWS. Reviews of important and timely subjects can be invited by the editorial board or
submitted independently. In the latter case, it is usually helpful for the corresponding author to consult
the Editor-in-Chief prior to submission. Reviews should focus on the critical aspects of a subject, linking
established knowledge to areas that remain controversial or unanswered. Reviews should normally
comprise less than 6,000 words, contain an unstructured abstract of 100 words or less, and use fewer
than 150 references; illustrations and tables should be used only to provide summaries or a synthesis of
ideas and/or data not included in the text.
REVIEWS OF BOOKS AND OTHER MEDIA FORMATS. Reviews of books,  lms, or other media formats
relevant to the scienti c or clinical practice of medicine, with particular importance to
hematology/oncology, may be invited or submitted independently. In the latter case, please consult with
the Editor-in-Chief prior to submission.
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CORRESPONDENCE. Correspondence should usually be in reference to previously published manuscripts
in American Journal of Hematology . However, correspondence relating to important and timely
publications or topics from other sources may also be appropriate. Brief descriptions of interesting
laboratory or clinical observations may also be appropriate. Correspondence to the Editor should be no
more 1,000 words, no more than 6 references and one table/ gure.
COMMENTARY. Commentaries are usually invited but may be submitted independently after consultation
with the Editor-in-Chief. Please limit the text to 2,500 words and fewer than 10 references. Commentaries
should focus on a controversial subject arising from a recently published American Journal of Hematology
manuscript, but they may also focus on independent and timely topics of relevance to the journal’s
readership. Illustrations and Tables are allowed only if they highlight or clarify points made in the text.
Commentaries will be reviewed and may require changes or be rejected.
MEETING REPORTS AND SUPPLEMENTS. Concise summaries of meetings that have important information
to convey to the readers of American Journal of Hematology are welcomed, but consultation with the
Editor-in-Chief should occur before submission. Summaries should emphasize the issues discussed at the
meeting along with an explanation of how they are important or controversial. Summaries should be less
than 2000 words. Illustrations and tables may be included but only when they add signi cantly to the text
content. More extensive reports with manuscripts from the speakers are also welcomed, but early
consultation with the Editor-in-Chief must take place in order to determine the type and number of
manuscripts to be published, the review process, and the procurement of additional funding if required.
TEST OF THE MONTH. Please consult with the Editor-in-Chief before submission. This new feature should
include a discussion of a speci c laboratory test/parameter that is relevant for hematologist/oncologists
and for any clinicians dealing with blood disorders. It should summarize technical speci cations and
issues, clinical performance and pitfalls, and provide evidence of sensitivity and speci city, particularly
discussing disease conditions if available. Manuscript length should be no more than 1,500 words with no
more than 25 references.
SOLVING CLINICAL PROBLEMS IN BLOOD DISEASES. The format of this case presentation should be
similar to that used in the Clinical problem-solving articles of the New England Journal of Medicine (see as
an example: Prasad M et al. New Engl J Med 2006 355:2468-2473 ). These articles should reproduce the
step-by-step process used by clinicians dealing with novel and/or unusually challenging clinical
presentations of hematological diseases. Clinical information must be presented in stages (boldface type),
followed by the clinical reasoning of the physician taking care of such a patient, and a  nal discussion of
the case as it relates to disease pathophysiology, complications, treatment, and treatment outcomes.
Manuscript length should be no more than 2,500 words, with no more than 25 references.
IMAGES IN HEMATOLOGY. We believe that the discipline of hematology lends itself particularly well to
visual case presentations. The purpose of this section of the Journal , therefore, is to present an
interesting visual description of a de ned hematological condition. The image may consist of a single
photo or a series of photos that, when grouped together, give a visual description of the speci c
hematological entity. It is expected that the submitting authors(s) will supplement the visual "Image" with
brief text as necessary to tell the full story. Whenever appropriate, we will publish the images in full color.
DIAGNOSTIC IMAGING IN HEMATOLOGY: a variety of techniques (X-rays, CT scans, MRI, Nuclear Medicine
scans and ultrasound) are routinely utilized in the diagnosis and treatment of hematological diseases. The
purpose of this section of the Journal is to provide images of techniques which provide relevant
diagnostic and clinical information for physicians managing patients a ected by Blood Diseases.
UPDATES IN CLINICAL TRAILS FOR HEMATOLOGICAL DISEASES. These are invited submissions, and any
submissions in this category must be cleared by the editor  rst. If you wish to submit in this category,
please contact the editorial o ce.
We work together with two Wiley’s open access journals, Clinical Case Reports and Cancer Medicine, to
enable rapid publication of good quality manuscripts that we are unable to accept for publication in our
journal. Authors may be o ered the option of having their paper, along with any related peer reviews,
automatically transferred for consideration by the Editor of either Clinical Case Reports or Cancer Medicine.
Authors will not need to reformat or rewrite their manuscript at this stage, and publication decisions will
be made a short time after the transfer takes place. Clinical Case Reports will consider case reports from
every clinical discipline and may include clinical images or clinical videos. The Editor of Cancer Medicine will
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accept submissions that report well-conducted research in oncology which reaches the standard
acceptable for publication. Clinical Case Reports and Cancer Medicine are open access journals, and article
publication fees apply. For more information please go to www.clinicalcasesjournal.com or
www.cancermedicinejournal.com.
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